ALT_logo
August 24, 2022
Recent News
- Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
- BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD
- The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors
- Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
- Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
- Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
